Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ferring Pharmaceuticals

< Previous 1 2 Next >
Ferring Pharmaceuticals to Explore Strategic Options for Rebyota®
From Ferring Pharmaceuticals
Via Business Wire
Ferring Highlights New Real-World Research with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals Presents Two New Analyses of Pivotal Trial Data for Follitropin Delta (FE 999049) at ASRM 2025
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2025
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents New Real-World REBYOTA® (fecal microbiota, live – jslm) Data Underscoring Effectiveness and Significant Improvements in Patient Quality of Life
From Ferring Pharmaceuticals
Via Business Wire
Ferring Expands Growing Body of Real-World Evidence Reinforcing Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Urology Practices
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals Recognizes World IVF Day by Partnering with Notable Advocates to Amplify the Conversation about Infertility
From Ferring Pharmaceuticals
Via Business Wire
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents New Phase 3b Safety and Effectiveness Data for Recurrent C. Diff Patients Receiving REBYOTA® (fecal microbiota, live – jslm) Via Colonoscopy, and Additional Analyses at DDW
From Ferring Pharmaceuticals
Via Business Wire
U.S. FDA Approves Second Drug Product Manufacturing Facility for ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Ferring Unveils New Data with ADSTILADRIN® (nadofaragene firadenovec-vncg) at 112th Annual Meeting of the Japanese Urological Association
From Ferring Pharmaceuticals
Via Business Wire
Ferring achieved record sales driven by Reproductive Medicine combined with the emergence of Adstiladrin
From Ferring Pharmaceuticals
Via Business Wire
First Real-World Outcomes Data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be Presented at 2025 ASCO Genitourinary Cancers Symposium
From Ferring Pharmaceuticals
Via Business Wire
Ferring Highlights Commitment to C. Diff Infection Community on the Second Anniversary of the Launch of REBYOTA® (fecal microbiota, live – jslm)
From Ferring Pharmaceuticals
Via Business Wire
Ferring Advances Three Studies in ADSTILADRIN® (nadofaragene firadenovec-vncg) Clinical Trial Program
From Ferring Pharmaceuticals
Via Business Wire
Ferring Announces U.S. FDA Advisory Committee Meeting for SI-6603 (condoliase), An Investigational Treatment in Lumbar Disc Herniation
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents New Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at ACG 2024
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals Illustrates Strong Commitment to Advancing Fertility Care at 2024 American Society for Reproductive Medicine Annual Congress
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents Real-World Outcomes Data Analyses for REBYOTA® (fecal microbiota, live – jslm) at IDWeek 2024
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility
From Ferring Pharmaceuticals
Via Business Wire
Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents Efficacy and Safety Data From Two Phase 3 Studies for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at NASS 2024
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present New Data Analysis at NASS 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
From Ferring Pharmaceuticals
Via Business Wire
Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024
From Ferring Pharmaceuticals
Via Business Wire
Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals and Posterity Health Launch New Partnership to Activate Men About Their Fertility
From Ferring Pharmaceuticals
Via Business Wire
Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC
From Ferring Pharmaceuticals
Via Business Wire
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
From Ferring Pharmaceuticals
Via Business Wire
Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
From Ferring Pharmaceuticals
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.